Wilson Marc's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Mar 20, 2024
- Accession no.
- 0001209191-24-005009
- Filed
- Mar 20, 2024
- Trade date
- Mar 18-19, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $297.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wilson MarcCIK 0001702265 | Officer (CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 18, 2024 | Common Stock | FTax withholdingDisposed | −3,983 | $38.14 | −$151,911.62 | 117,572 | Direct | |
| Mar 19, 2024 | Common Stock | SSaleDisposed | −6,942 | $42.91F3 | −$297,881.22 | 110,630 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $42.91 per share. The range of sales prices on the transaction date was $41.04 to $44.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.